Teva pulls its Meridia version in Israel; Warner Chilcott gets FDA nod for bone drug;

 @FiercePharma: Sanofi cuts 1,700 U.S. jobs. Article | Follow @FiercePharma

> Teva Pharmaceutical Industries, which has marketed Abbott Laboratories' weight loss pill Meridia in Israel, has pulled the drug, sold in that country as Reductil. Report

> Warner Chilcott won the FDA's nod for its tablet drug, Atelvia, for postmenopausal osteoporosis; it plans a commercial launch in the U.S. early next year. Warner Chilcott release | Report

> Since its launch September 15 through late last week, Eli Lilly's new blog and social-media effort LillyPad has received roughly 8,300 unique web visitors and more than 25,000 page views. Report

> Janssen U.K. has officially launched its new psoriasis disease awareness campaign, part of which includes the first pharma Facebook page to allow comments before they have been checked and approved. Report

> Sales of drugs to treat ulcerative colitis in seven major markets will grow by "a modest" $800 million to 2019, forecasts a new report. Report

> The Drug Enforcement Administration has issued a new guideline intended to help ease the delay some nursing home residents face in receiving certain painkillers and anti-anxiety medications. Report

> German drugmaker Merck KGaA plans to ask a European watchdog to review a negative opinion issued on multiple sclerosis drug cladribine last month that said the drug's risks outweighed its benefits. Report

> Bayer Schering Pharma has concluded the European registration procedure for introducing Qlaira in the new indication treatment of heavy menstrual bleeding. Report

> AstraZeneca's chief executive will this week urge ministers to work with the pharmaceutical industry to share the risks and costs in developing effective antibiotics and other treatments. Report

Biotech News

 @FierceBiotech: Boehringer stops female libido drug program. Article | Follow @FierceBiotech

 @JohnCFierce: Happy to see Mario Vargas Llosa win the Nobel this week. Can't remember the last time they gave it to someone whose work I know. |  Follow @JohnCFierce

> Alexza shares plunge as FDA refuses to approve AZ-004. Item

> Jazz shares hit sour note as FDA rejects fibromyalgia drug. Report

> Novartis jumps on board ImmunoGen's hot antibody platform. News

> J&J touts PhIII boost in prostate cancer patients' survival rates. Story

> BMS re-ups with Exelixis in $565M development deal. Report

Biotech IT News

> Data drives adaptations in I-Spy 2 cancer trial. News

> Drug-use software aids may siphon development funds. Story

> Investigator warned for record-keeping violations. Item

> BioClinica EDC deal should help settle investor Nicusa. Article

> Verizon cloud hosts app that measures wound-healing progress. Story

> Free smartphone app evaluates need for radionuclide imaging. Report

And Finally ... Pharmacy-benefit manager Express Scripts is unveiling a new program that aims to contact people who fail to take their prescription drugs-before they actually stop. Express Scripts release |  Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.